Advances in Chronic Kidney Disease
Volume 17, Issue 4 , Pages 320-328 , July 2010

Medication Issues in Older Individuals With CKD

  • Dena E. Rifkin

      Affiliations

    • Divisions of Nephrology and Family and Preventive Medicine, Veterans' Affairs Medical Center, San Diego, and the University of California, San Diego, CA
    • ,
  • Wolfgang C. Winkelmayer

      Affiliations

    • Division of Nephrology, Stanford University School of Medicine, Palo Alto, CA
    • Corresponding Author InformationAddress correspondence to Wolfgang C. Winkelmayer, MD, ScD, Division of Nephrology, Stanford University School of Medicine, 780 Welch Rd, Ste 106, Palo Alto, CA 94304.

References 

  1. Centers for Disease Control and Prevention, Public health and aging: Trends in aging—United States and worldwide. MMWR Morb Mortal Wkly Rep. 2003;52:101–106
  2. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298:2038–2047
  3. National Kidney Foundation: K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 Suppl 1):S1–S266
  4. Keith DS, Nicholas GA, Gullion CM, et al. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med. 2004;164:659–663
  5. Prevalence of selected conditions by age and sex: United States, 1984-1995. NHIS (NHIC95); Centers for Disease Control/National Center for Health Statistics. Available at: http://www.cdc.gov/nchs/agingact.htm. Accessed June 2008.
  6. Fried LF, Shilpak MG, Crump C, et al. Renal insufficiency as a predictor of cardiovascular outcomes and mortality in elderly individuals. J Am Coll Cardiol. 2003;41:1364–1372
  7. Manjunath G, Tighiouart H, Coresh J, et al. Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. Kidney Int. 2003;63:1121–1129
  8. Agostini JV, Han L, Tinetti ME. The relationship between number of medications and weight loss or impaired balance in older adults. J Am Geriatr Soc. 2004;52:1719–1723
  9. Hug BL, Witkowski DJ, Sox CM, et al. Occurrence of adverse, often preventable, events in community hospitals involving nephrotoxic drugs or those excreted by the kidney. Kidney Int. 2009;76:1192–1198
  10. Gill SS, Mamdani M, Naglie G, et al. A prescribing cascade involving cholinesterase inhibitors and anticholinergic drugs. Arch Intern Med. 2005;165:808–813
  11. Hayes TL, Larimer N, Adami A, et al. Medication adherence in healthy elders: Small cognitive changes make a big difference. J Aging Health. 2009;21:567–580
  12. Turner BJ, Hollenbeak C, Weiner MG, et al. Barriers to adherence and hypertension control in a racially diverse representative sample of elderly primary care patients. Pharmacoepidemiol Drug Saf. 2009;18:672–681
  13. Kennedy J, Morgan S. Cost-related prescription nonadherence in the United States and Canada: A system-level comparison using the 2007 International Health Policy Survey in Seven Countries. Clin Ther. 2009;31:213–219
  14. Madden JM, Graves AJ, Ross-Degnan A, et al. Cost-related medication nonadherence after implementation of Medicare Part D, 2006-2007. JAMA. 2009;302:1755–1756
  15. Fick DM, Cooper JW, Wade WE, et al. Updating the Beers criteria for potentially inappropriate medication use in older adults: Results of a US consensus panel of experts. Arch Intern Med. 2003;163:2716–2724
  16. Goulding MR. Inappropriate medication prescribing for elderly ambulatory care patients. Arch Intern Med. 2004;164:305–312
  17. Budnitz DS, Shehab N, Kegler SR, et al. Medication use leading to emergency department visits for adverse drug events in older adults. Ann Intern Med. 2007;147:755–765
  18. Johnell K, Klarin I. The relationship between number of drugs and potential drug-drug interactions in the elderly: A study of over 600,000 elderly patients from the Swedish Prescribed Drug Register. Drug Saf. 2007;10:911–918
  19. Kaufman DW, Kelly JP, Rosenberg L, et al. Recent patterns of medication use in the ambulatory adult population of the United States: The Slone survey. JAMA. 2002;287:337–344
  20. Caskie GI, Willis SL, Warner Schaie K, et al. Congruence of medication information from a brown bag data collection and pharmacy records: Findings from the Seattle longitudinal study. Exp Aging Res. 2006;32:79–103
  21. Williams ME, Pulliam CC, Hunter R, et al. The short-term effect of interdisciplinary medication review on function and cost in ambulatory elderly people. J Am Geriatr Soc. 2004;52:93–98
  22. Rathore SS, Mehta SS, Boyko WL, et al. Prescription medication use in older Americans: A national report card on prescribing. Fam Med. 1998;30:733–739
  23. Masoudi FA, Rathore SS, Wang Y, et al. National patterns of use and effectiveness of angiotensin-converting enzyme inhibitors in older patients with heart failure and left ventricular systolic dysfunction. Circulation. 2004;110:724–731
  24. Kuijpers MA, van Marum RJ, Egberts AC, et al. Relationship between polypharmacy and underprescribing. Br J Clin Pharmacol. 2008;65:130–133
  25. Stevens LA, Viswanathan G, Weiner DE. Chronic kidney disease - Q2 and end-stage renal disease in the elderly population: Current prevalence, future projections, and clinical significance. ACKD. 2010;17:293–301
  26. Gill J, Malyuk R, Djurdjev O, et al. Use of GFR equations to adjust drug doses in an elderly multi-ethnic group—a cautionary tale. Nephrol Dial Transplant. 2007;22:2894–2899
  27. Fink JC, Brown J, Hsu VD, et al. CKD as an underrecognized threat to patient safety. Am J Kidney Dis. 2009;53:681–688
  28. Winkelmayer WC, Fischer MA, Schneeweiss S, et al. Underuse of ACE inhibitors and angiotensin II receptor blockers in elderly patients with diabetes. Am J Kidney Dis. 2005;46:1080–1087
  29. Elias MF, Elias PK, Seliger SL, et al. Chronic kidney disease, creatinine and cognitive functioning. Nephrol Dial Transplant. 2009;24:2446–2452
  30. Hedayati SS, Minhajuddin AT, Toto RD, et al. Prevalence of major depressive episode in CKD. Am J Kidney Dis. 2009;54:424–432
  31. Watnick S, Kirwin P, Mahnensmith R, et al. The prevalence and treatment of depression among patients starting dialysis. Am J Kidney Dis. 2003;41:105–110
  32. Wilhelm-Leen ER, Hall YN, Tamura MK, et al. Frailty and chronic kidney disease: The Third National Health and Nutrition Evaluation Survey. Am J Med. 2009;122:664–671e2
  33. Tinetti ME, Bogardus ST, Agostini JV. Potential pitfalls of disease-specific guidelines for patients with multiple conditions. N Engl J Med. 2004;351:2870–2874
  34. UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703–713
  35. Estacio RO, Jeffers BW, Hiatt WR, et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. New Engl J Med. 1998;338:645–652
  36. Klahr S, Levey AS, Beck GJ, et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med. 1994;330:877–884
  37. Lewis JB, Berl T, Brain RP, et al. Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy. Collaborative Study Group. Am J Kidney Dis. 1999;34:809–817
  38. Ruggenenti P, Perna A, Loriga G, et al. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): Multicentre, randomised controlled trial. Lancet. 2005;365:939–946
  39. Schrier RW, Estacio RO, Esler A, et al. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int. 2002;61:1086–1097
  40. Wright JT, Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: Results from the AASK trial. JAMA. 2002;288:2421–2431
  41. Snyder JJ, Collins AJ. KDOQI hypertension, dyslipidemia, and diabetes care guidelines and current care patterns in the United States CKD population: National Health and Nutrition Examination Survey 1999-2004. Am J Nephrol. 2009;30:44–54
  42. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA. 2003;289:2560–2572
  43. Peralta CA, Hicks LS, Chertow GM, et al. Control of hypertension in adults with chronic kidney disease in the United States. Hypertension. 2005;45:1119–1124
  44. Winkelmayer WC, Zhang Z, Shahinfar S, et al. Efficacy and safety of angiotensin II receptor blockade in elderly patients with diabetes. Diabetes Care. 2006;29:2210–2217
  45. Perazella MA, Mahnensmith RL. Hyperkalemia in the elderly: Drugs exacerbate impaired potassium homeostasis. J Gen Intern Med. 1997;12:646–656
  46. Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: Is this a cause for concern?. Arch Intern Med. 2000;160:685–693
  47. Balamuthusamy S, Srinivasan L, Verma M, et al. Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: A meta-analysis. Am Heart J. 2008;155:791–805
  48. Einhorn LM, Zhan M, Hsu VD, et al. The frequency of hyperkalemia and its significance in chronic kidney disease. Arch Intern Med. 2009;169:1156–1162
  49. Pappoe LS, Winkelmayer WC. ACE inhibitor and angiotensin II type 1 receptor antagonist therapies in elderly patients with diabetes mellitus: Are they underutilized?. Drugs Aging. 2010;27:87–94
  50. Coca SG, Krumholz HM, Garg AX, et al. Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease. JAMA. 2006;296:1377–1384
  51. Charytan D, Kuntz RE. The exclusion of patients with chronic kidney disease from clinical trials in coronary artery disease. Kidney Int. 2006;70:2021–2030
  52. Tonelli M, Isles C, Curhan GC, et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation. 2004;110:1557–1563
  53. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–1305
  54. Ezekowitz J, McAlister FA, Humphries KH, et al. The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease. J Am Coll Cardiol. 2004;44:1587–1592
  55. Winkelmayer WC, Charytan DM, Brookhart MA, et al. Kidney function and use of recommended medications after myocardial infarction in elderly patients. Clin J Am Soc Nephrol. 2006;1:796–801
  56. Winkelmayer WC, Levin R, Setoguchi S. Associations of kidney function with cardiovascular medication use after myocardial infarction. Clin J Am Soc Nephrol. 2008;3:1415–1422
  57. Berger AK, Duval S, Manske C, et al. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure and chronic kidney disease. Am Heart J. 2007;153:1064–1073
  58. Tonelli M, Isles C, Craven T, et al. Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation. 2005;112:171–178
  59. Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol. 2004;57:728–734
  60. Sandhu S, Wiebe N, Fried LF, et al. Statins for improving renal outcomes: A meta-analysis. J Am Soc Nephrol. 2006;17:2006–2016
  61. Fellstrom BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360:1395–1407
  62. Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353:238–248
  63. Moen MF, Zhan M, Hsu VD, et al. Frequency of hypoglycemia and its significance in chronic kidney disease. Clin J Am Soc Nephrol. 2009;4:1121–1127
  64. Gerstein HC, Miller ME, Byrington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–2559
  65. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129–139
  66. Adhiyaman V, Asghar M, Oke A, et al. Nephrotoxicity in the elderly due to co-prescription of angiotensin converting enzyme inhibitors and nonsteroidal anti-inflammatory drugs. J R Soc Med. 2001;94:512–514
  67. Gooch K, Culleton BF, Manns BJ, et al. NSAID use and progression of chronic kidney disease. Am J Med. 2007;120:280;e1-e7
  68. Winkelmayer WC, Waikar SS, Mogun H, et al. Nonselective and cyclooxygenase-2-selective NSAIDs and acute kidney injury. Am J Med. 2008;121:1092–1098
  69. Laliberte MC, Normandeau M, Lord A, et al. Use of over-the-counter medications and natural products in patients with moderate and severe chronic renal insufficiency. Am J Kidney Dis. 2007;49:245–256
  70. Winkelmayer WC, Mehta J, Wang PS. Benzodiazepine use and mortality of incident dialysis patients in the United States. Kidney Int. 2007;72:1388–1393
  71. Mehrotra R, Kermah DA, Salusky IB, et al. Chronic kidney disease, hypovitaminosis D, and mortality in the United States. Kidney Int. 2009;76:977–983
  72. Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355:2071–2084
  73. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085–2098
  74. Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361:2019–2032
  75. Blix HS, Viktil KK, Moger TA, et al. Use of renal risk drugs in hospitalized patients with impaired renal function–an underestimated problem?. Nephrol Dial Transplant. 2006;21:3164–3171
  76. Corsonello A, Pedone C, Corica F, et al. Concealed renal insufficiency and adverse drug reactions in elderly hospitalized patients. Arch Intern Med. 2005;165:790–795
  77. Salomon L, Deray G, Jaudon MC, et al. Medication misuse in hospitalized patients with renal impairment. Int J Qual Health Care. 2003;15:331–335

 Dr. Rifkin has nothing to disclose; Dr. Winkelmayer's recent support includes a Scientist Development Grant from the American Heart Association, a Norman S. Coplon Extramural Research Program Award from Satellite Healthcare, Inc., support from the National Institutes of Health, and investigator-initiated grants from Amgen and GlaxoSmithKline. In the last 3 years, he has participated in advisory boards or been a consultant to AMAG Pharmaceuticals, Amgen, Fibrogen, and Fresenius, MD, MPH, ScD, FASN.

PII: S1548-5595(10)00048-0

doi: 10.1053/j.ackd.2010.03.005

Advances in Chronic Kidney Disease
Volume 17, Issue 4 , Pages 320-328 , July 2010

Article Tools